14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
RBB vs KIDS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, RBB Bancorp (RBB) captures the overall head-to-head institutional edge over OrthoPediatrics Corp. (KIDS) on higher Unified Composite conviction (37.6/100 SELL vs. 45.1/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while KIDS wins 3–2 across the 6-pillar growth and valuation breakdown. RBB trades at $24.41 (10.3x Forward P/E, 43.6% operating margin) versus KIDS at $32.51 (N/M Forward P/E, -8.2% operating margin).
Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. RBB 37.6/100 SELL), RBB captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (43.6% vs. -8.2% operating margin) and revenue trajectory (+13.8% vs. +18.6% YoY).
Technical & Structure Timing Caution: RBB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.2); meanwhile KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBB vs KIDS. Trailing 12-month operating profitability (RBB 43.6% vs KIDS -8.2%) and valuation multiples (RBB 10.3x vs KIDS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment82.0% of Rev ($217M)
90D Engineering Disclosures0 Published
Investor FAQ RBB vs KIDS Key Questions & Quantitative Answers
As of Nov 19, 2026, RBB Bancorp (RBB) captures the overall head-to-head institutional edge over OrthoPediatrics Corp. (KIDS) on higher Unified Composite conviction (37.6/100 SELL vs. 45.1/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while KIDS wins 3–2 across the 6-pillar growth and valuation breakdown. RBB trades at $24.41 (10.3x Forward P/E, 43.6% operating margin) versus KIDS at $32.51 (N/M Forward P/E, -8.2% operating margin). Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. RBB 37.6/100 SELL), RBB captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (43.6% vs. -8.2% operating margin) and revenue trajectory (+13.8% vs. +18.6% YoY). Technical & Structure Timing Caution: RBB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.2); meanwhile KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KIDS leads the Growth & Scale pillar: RBB posts +13.8% YoY revenue growth and +25.6% YoY earnings growth on $131M TTM revenue (100.0% gross margin, 43.6% operating margin), compared with KIDS at +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin). On trailing 12-month operating scale, RBB generates $131M in USD-normalized revenue versus $264M for KIDS. In operating R&D and SG&A reinvestment, RBB deploys 56.4% of Rev ($74M) (0 90-day corporate R&D disclosures) versus 82.0% of Rev ($217M) (0 disclosures) for KIDS.
RBB screens cheaper on headline valuation multiples. RBB trades at 10.3x Forward P/E, 9.4x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (unreported cash flow margin), whereas KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBB (8.4% ROE) versus KIDS (-9.8% ROE) capital efficiency.
In options market volatility and institutional positioning, RBB carries 40.7% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.42β · 18% Vol realized risk). By comparison, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.